WHAT IF WE COULD CREATE PRECISION ANTI-CANCER MEDICINES THAT TARGET TUMOR CELLS?
That’s the goal at Epochal Precision Anti-Cancer Therapeutics (EPAT),
our Biologics Discovery Center located in Exton, Pennsylvania.
EPAT is developing precision oncology therapies by combining
biologics expertise, Eisai’s unique Antibody-Drug Conjugate (ADC)
technology, proprietary payloads and
- Women’s cancers, including gynecologic cancers and breast cancer
- Stroma-rich malignant cancers, including pancreatic cancer, triple negative breast cancer and scirrhous gastric cancer
*Any ADC employing eribulin as a payload is investigational and has not been approved by regulatory authorities. For more information on HALAVEN® (eribulin mesylate), please see www.halaven.com or contact Eisai’s Medical Information toll-free number: 1-888-274-2378.
EXPLORE THE SCIENCE BEHIND EPAT’S NEXT-GENERATION PROGRAMS
Get an in-depth look at EPAT’s proprietary technologies, including: